背景:荨麻疹是一种以风团(荨麻疹)发展为特征的病症,血管性水肿,或者两者兼而有之。如果症状持续少于6周,它被归类为急性荨麻疹(AU),如果它们持续超过6周,它被归类为慢性荨麻疹(CU)。使用经过验证的患者报告的结果测量(PROM)评估疾病活动,例如7天荨麻疹活动评分(UAS-7)和荨麻疹控制测试(UCT)。在这项研究中,我们的目的是确定慢性和恢复性荨麻疹患者在年龄方面是否存在差异,性别,症状,疾病严重程度,疾病控制,并通过跟踪AU患者6个月来触发因素。
方法:患者首次入院时要求进行常规检查。如果以前检查过,抗甲状腺过氧化物酶(抗TPO),抗核抗体,等。,被记录下来。第一次检查后,使用视觉模拟量表(VAS)再次评估患者,UCT,UAS-7和药物评分(MS)在1,3rd,第六个月。
结果:研究中纳入了109例(F/M:80/29)患者。27例患者有AU病史,其中22例患者被评估为复发性AU,在随访期间有5人成为慢性疾病。在第3个月出现首次发作AU的82例患者中,有22例继续出现荨麻疹,在第6个月出现17例。我们的慢性病率为24.7%。确定具有阳性抗TPO的CU风险增加1.69倍。在平均VAS中发现了统计学上的显着改善,UCT,UAS-7,MS在第1次评估,3rd,与基线相比,CU患者的第6个月。
结论:AU是一种常见疾病,通常在短时间内治愈而不会成为慢性疾病。关于慢性原因的研究是有限的。在AU患者中测试抗TPO可能在病程和慢性风险方面有用。
BACKGROUND: Urticaria is a condition that is characterized by the development of wheals (hives), angioedema, or both. If symptoms persist for less than 6 weeks, it is classified as acute urticaria (AU), and if they persist for longer than 6 weeks, it is classified as chronic urticaria (CU). Disease activity is evaluated using validated patient-reported outcome measures (PROMs) such as the 7-day urticaria activity score (UAS-7) and urticaria control test (UCT). In this study, we aimed to determine whether there was a difference between patients with chronic and recovered urticaria in terms of age, sex, symptoms, disease severity, disease control, and triggering factors by following patients with AU for 6 months.
METHODS: The routine tests were requested at the first admission of the patients. If previously examined, anti-thyroid peroxidase (anti-TPO), anti-nuclear antibody, etc., were recorded. After the first examination, the patients were evaluated again using a visual analog scale (VAS), UCT, UAS-7, and medication scores (MSs) in the 1st, 3rd, and 6th months.
RESULTS: One hundred nine (F/M: 80/29) patients were included in the study. Twenty-seven patients had a previous history of AU, 22 of these patients were evaluated as having recurrent AU, and five became chronic during follow-up. Urticaria continued in 22 of 82 patients who presented with first-attack AU in the 3rd month and 17 in the 6th month. We had a chronicity rate of 24.7%. It was determined that having positive anti-TPO increased the risk of CU 1.69 times. A statistically significant improvement was found in the mean VAS, UCT, UAS-7, and MSs evaluated in the 1st, 3rd, and 6th months of patients with CU compared with baseline.
CONCLUSIONS: AU is a common disease and usually heals in a short time without becoming chronic. Studies on the causes of chronicity are limited. Testing anti-TPO in patients presenting with AU may be useful in terms of disease course and risk of chronicity.